Welcome to our dedicated page for Qilian International Holding Group Ltd. Ordinary Shares news (Ticker: QLI), a resource for investors and traders seeking the latest updates and insights on Qilian International Holding Group Ltd. Ordinary Shares stock.
Qilian International Holding Group Ltd. (QLI) is a leading Chinese manufacturer specializing in pharmaceutical products and chemical derivatives, with core focus on traditional medicine innovations and biomedical materials. This news hub provides investors and industry observers with essential updates on the company’s strategic developments across its diversified operations.
Access comprehensive coverage of QLI’s financial announcements, product innovations, and market adaptations. Our curated news collection enables stakeholders to track the company’s evolving focus areas including heparin sodium production, licorice-based remedies, and technological investments while monitoring operational adjustments in response to industry trends.
Key updates include earnings reports, manufacturing expansions, regulatory milestones, partnership announcements, and strategic shifts across pharmaceutical, chemical, and technology segments. Content spans operational updates from Gansu production facilities to Chengdu-based R&D initiatives.
Bookmark this page for streamlined access to verified QLI developments, ensuring informed decision-making through centralized monitoring of this dynamic manufacturer’s progress in traditional and emerging markets.
Qilian International Holding Group , a China-based pharmaceutical and chemical products manufacturer, has announced a change in its trading ticker symbol on the Nasdaq Capital Market. Effective August 11, 2024, the company's Class A ordinary shares will trade under the new symbol 'BGM', replacing the current symbol 'QLI'. This change does not require any action from shareholders, and the company's CUSIP number remains unchanged. Qilian will continue to be listed on the Nasdaq Capital Market.
Qilian International Holding Group (NASDAQ: QLI), a China-based pharmaceutical and chemical products manufacturer, has regained compliance with NASDAQ's minimum bid price rule. On July 10, 2024, NASDAQ informed Qilian that for ten consecutive business days, from June 21 to July 9, 2024, the closing bid price of its Class A ordinary shares remained at or above $1.00 per share. This compliance with Listing Rule 5550(a)(2) means NASDAQ has closed the matter.
Qilian International Holding Group (NASDAQ: QLI) has announced a 1 for 5 reverse share split, effective June 21, 2024. Approved on May 29, 2023, this split will reduce the number of issued and outstanding Class A and Class B ordinary shares. The new Class A shares are expected to trade at five times their previous price, though this is not guaranteed. Shareholders will receive one new share for every five shares held. Post-split, Qilian's authorized share capital will consist of 70 million Class A shares, 20 million Class B shares, and 10 million preferred shares. Fractional shares will be rounded up to the nearest whole share.
Qilian International (NASDAQ: QLI) has announced plans to adjust its industrial investments in response to declining demand and increasing costs in its oxytetracycline sector. The company will significantly reduce its investment in oxytetracycline and increase its focus on heparin sodium, a biomedical raw material with promising market potential. Additionally, Qilian will expand its licorice product line and invest in financial technology and software development. These strategic shifts aim to optimize resource allocation, boost efficiency, and enhance overall competitiveness and profitability.
Qilian International Holding Group (NASDAQ: QLI) announced it has regained compliance with NASDAQ Listing Rule 5250(c)(1) after filing its annual report on Form 20-F on April 19, 2023. This report covered the financial year ended September 30, 2022, and resolved previous non-compliance issues cited in a notice received on February 16, 2023. Following the filing, NASDAQ confirmed the matter closed on April 20, 2023. Qilian, based in Gansu, China, specializes in manufacturing pharmaceutical and chemical products, including licorice and oxytetracycline products, serving over 20 provinces in China. The company emphasizes the importance of meeting regulatory requirements to maintain its listing status.
Qilian International Holding Group Ltd (NASDAQ: QLI) announced on February 23, 2023, that it received a notice of non-compliance from Nasdaq for not timely filing its annual report on Form 20-F for the year ending September 30, 2022. This notice does not immediately affect Qilian’s listing or trading on Nasdaq. The company has 60 days to submit a compliance plan, and if accepted, it could gain an additional 180 days until August 14, 2023, to comply with Nasdaq Listing Rule 5250(c)(1).
Qilian, based in Gansu, China, manufactures pharmaceutical and chemical products, selling in over 20 provinces.
On February 16, 2023, Qilian International Holding Group Ltd (NASDAQ: QLI) announced a special one-time cash dividend of
Qilian International Holding Group Limited (Nasdaq: QLI) reported financial results for the first six months of fiscal year 2022, ending March 31, 2022, showing revenues of approximately $32.1 million, up 7% year-over-year. However, net income plummeted by 89% to $249,681, primarily due to rising raw material costs. Gross profit decreased by 31% to $2.8 million, reflecting a decline in gross margin from 13.7% to 8.8%. The company expects growth in 2023 with the completion of ongoing construction projects and improved pandemic control.
FAQ
What is the current stock price of Qilian International Holding Group Ltd. Ordinary Shares (QLI)?
What is the market cap of Qilian International Holding Group Ltd. Ordinary Shares (QLI)?
